Abeona Therapeutics Receives FDA Orphan Drug Designation For ABO-202 Gene Therapy Program In Infantile Batten … – Clinical Leader
|
Abeona Therapeutics Receives FDA Orphan Drug Designation For ABO-202 Gene Therapy Program In Infantile Batten …
Clinical Leader Abeona Therapeutics Inc, a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced recently that the FDA has granted Orphan Drug Designation (ODD) to its … |
